The importance of selected biomarkers in the clinical practice of breast cancer patients

Breast cancer is considered the most commonly diagnosed tumors. Biomarkers used for diagnosis and treatment of breast are: tissue biomarkers (PR, ER, HER2, Ki-67) serum (CA15-3, CA125, CA27.29, CEA, cytokeratins). ECD metalloproteinases leptin are emerging promising cancer. There a growing need personalized diagnostics based on tumor genome characterization, relying liquid biopsy containing components such as CTC ctDNA, cell-free RNA. can also be use target anti (PGRN sortilin, AR, PD-1/PD-L1). Another potential fields application monitoring side effects, us inflammatory causing cardiotoxicity, thyroiditis (TSH, FT4, TPOab TgAb) in IrAE, NF-L MCP-1 ICI-associated neurotoxity. It expected to develop new prognostic predictive that would provide accurate reliable information clinical application. Through recognition biomarkers, it possible identify subgroups patients who benefit from targeted therapies managing by effects. However, these validated tested their suitability before entering use.